CHRS Q3 2021 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$219M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$83M-27.3% YoY

Gross Profit

$61M74.2% margin

Operating Income

-$33M-39.7% margin

Net Income

-$39M-46.7% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

-5.9%

Cash Flow

Operating Cash Flow

$14M

Free Cash Flow

$13M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$742M

Total Liabilities

$611M

Stockholders' Equity

$131M

Cash & Equivalents

$361M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$83M	$114M	-27.3%
Gross Profit	$61M	$105M	-41.4%
Operating Income	-$33M	$34M	-197.2%
Net Income	-$39M	$28M	-237.9%

Revenue Segments

Product

$83M100%